AstraZeneca CEO “We will conduct global clinical trials for additional corona vaccines”

Further global clinical trials are expected to proceed amid doubts about the efficacy of the COVID-19 vaccine developed by the University of Oxford in the UK and multinational pharmaceutical company AstraZeneca.

In an interview with Bloomberg News, CEO Pascal Sorio AstraZeneca told Bloomberg that “we have found a way that works better, so we have to prove it.”

This means that more research will be undertaken on a low-dose regimen, in which the vaccine’s immune effect reaches 90%.

Previously, AstraZeneca and the University of Oxford had announced that the average immune effect was 70% as a result of the initial analysis of data from a phase 3 clinical trial of a vaccine under development.

Participants who took half the vaccine dose first and a full dose one month later had a 90% prophylactic effect and those who took the full dose of both doses were 62%.

The researchers say they still don’t know why the immune effects differ by dosage.

Additionally, all participants who received half the dose in the first dose were under 55 and it was later revealed that there were no elderly people and the suspicion that key information had been omitted.